China Vaccine Maker Licenses Pneumonia Vaccines Of U.S. Firm
This article was originally published in PharmAsia News
Executive Summary
China's Chengdu Institute of Biological Products has agreed to license pneumonia vaccines from U.S.-based Fina Biosolutions for what could amount to $850,000 in royalties and milestone payments.